Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1060]
News [2279]
Articles [128]
Editorials [8]
Conferences [91]
elearning [10]
ESMO 2023: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
8 Nov 2023
Adjuvant radiotherapy has no benefit following radical prostatectomy
Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK
Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )
27 Oct 2023
PARPi combinations to treat patients with mCRPC
Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof...
PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Prof Karim Fizazi, Prof Laura-Maria Krabbe and Prof Gerhardt Attard )
25 Oct 2023
Where do we stand with mCRPC?
Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike...
Where do we stand with mCRPC? ( Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike Schlurmann )
25 Oct 2023
ESMO 2023: Latest updates in mRCC
Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane...
ESMO 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane Oudard )
23 Oct 2023
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced...
Prof Thomas Powles - Barts Cancer Centre, London, UK
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )
22 Oct 2023
Belzutifan improves PFS, ORR in clear cell renal cell carcinoma
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Belzutifan improves PFS, ORR in clear cell renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
22 Oct 2023
Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC
Dr Michiel Van der Heijden - Netherlands Cancer Institute, Amsterdam...
Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC ( Dr Michiel Van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
22 Oct 2023
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
22 Oct 2023
A biomarker led approach to bladder cancer
Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...
A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )
22 Oct 2023
Myeloma Treatment and Prognosis
Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion medicine...
Myeloma Treatment and Prognosis ( Dr Maitreyyee Bhattacharyya - Institute of Hematology and Transfusion medicine, Medical College, Kolkata )
10 Oct 2023
Imaging and intervention in thyroid lesions
Dr Dayanand Lingegowda - TMC, Kolkata
Imaging and intervention in thyroid lesions ( Dr Dayanand Lingegowda - TMC, Kolkata )
9 Oct 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation